The immunohistochemical expression of CTLA-4, PD-1, and PD-L1 in tumor-infiltrating lymphocytes has also been evaluated as a predictive marker of response to ICIs in melanoma patients with controversial results. The gene discussed is CTLA4; the disease is melanoma.